FIELD: organic chemistry.
SUBSTANCE: invention relates to a compound or its pharmaceutically acceptable salt of formula I, where R1 is selected from hydrogen, amino and hydroxy-substituted C1-2 alkyl; R2 is hydrogen; R3 is selected from C1-2 alkyl and halo-substituted C1-2 alkyl; R4 is hydrogen; R5 is selected from hydrogen and halogen; and R6 is selected from hydrogen and halogen. The invention also relates to a specific compound of formula I, a pharmaceutical composition based on a compound of formula I, and a method for treating a BRM-mediated and/or BRG1-mediated disorder or disease.
EFFECT: effective treatment of a BRM-mediated and/or BRG1-mediated disorder or disease.
10 cl, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 1-(4-AMINO-5-BROMO-6-(1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)-1H-PYRAZOL-4-OL AND ITS APPLICATIONS FOR CANCER TREATMENT | 2018 |
|
RU2791531C2 |
| ANTIBODY-DRUG CONJUGATES CONTAINING HERBOXYDIENE-BASED SPLICING MODULATOR, AND METHODS OF USE THEREOF | 2019 |
|
RU2820607C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USE THEREOF IN TREATING DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 OF IKAROS (IKZF2) FAMILY | 2019 |
|
RU2815714C2 |
| 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 (IKZF2) OF THE IKAROS FAMILY | 2019 |
|
RU2797559C2 |
| SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2019 |
|
RU2815199C2 |
| CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2826119C1 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| METHODS, COMPOSITIONS AND IMPLANTED ELEMENTS CONTAINING ACTIVE CELLS | 2018 |
|
RU2826206C2 |
